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The histamine H4 receptor: from
orphan to the clinic
Robin L. Thurmond*
Janssen Research & Development, LLC, San Diego, CA, USA
The histamine H4 receptor (H4R) was first noted as a sequence in genomic databases
that had features of a class A G-protein coupled receptor. This putative receptor was
found to bind histamine consistent with its homology to other histamine receptors
and thus became the fourth member of the histamine receptor family. Due to the
previous success of drugs that target the H1 and H2 receptors, an effort was made
to understand the function of this new receptor and determine if it represented a viable
drug target. Taking advantage of the vast literature on the function of histamine, a search
for histamine activity that did not appear to be mediated by the other three histamine
receptors was undertaken. From this asthma and pruritus emerged as areas of particular
interest. Histamine has long been suspected to play a role in the pathogenesis of
asthma, but antihistamines that target the H1 and H2 receptors have not been shown
to be effective for this condition. The use of selective ligands in animal models of
asthma has now potentially filled this gap by showing a role for the H4R in mediating
lung function and inflammation. A similar story exists for chronic pruritus associated
with conditions such as atopic dermatitis. Antihistamines that target the H1 receptor
are effective in reducing acute pruritus, but are ineffective in pruritus experienced by
patients with atopic dermatitis. As for asthma, animal models have now suggested a
role for the H4R in mediating pruritic responses, with antagonists of the H4R reducing
pruritus in a number of different conditions. The anti-pruritic effect of H4R antagonists
has recently been shown in human clinical studies, validating the preclinical findings in
the animal models. A selective H4R antagonist inhibited histamine-induced pruritus in
health volunteers and reduced pruritus in patients with atopic dermatitis. The history
to date of the H4R provides an excellent example of the deorphanization of a novel
receptor and the translation of this into clinical efficacy in humans.
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Introduction
There are now four known G-coupled protein receptors (GPCRs) that use histamine as a ligand.
These receptors were discovered over a span of almost 100 years and each discovery provides excel-
lent examples of the use of state-of-the-art receptor pharmacology to discovery new receptors.
The ﬁrst actions of histamine were noted around 1910 (Barger and Dale, 1910; Dale and Laidlaw,
1911), but this before the idea of receptors was widely accepted. After the development of com-
pounds that blocked the eﬀect of histamine in the 1930–1940s, it was noted that their eﬀects were
consistent with a competition for binding at a receptor now known as the histamine H1 receptor
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(H1R; Wells et al., 1945). These ﬁrst antihistamines became the
basis for very successful drugs, some of which are still in use
today. However, they also revealed new questions since there were
actions of histamine that were not blocked by these ligands. This
led to the proposal that a second histamine receptor existed (Ash
and Schild, 1966), and the discovery of selective ligands for this
receptor led to its pharmacological characterization and the des-
ignation as the H2R (Black et al., 1972). A similar story exist
for the discovery of the H3R, where it was noted that various
histamine receptor ligands modulated histamine actions in the
brain, but that the pharmacology did not match the known H1R
and H2R (Arrang et al., 1983).
Discovery of the Histamine H4
Receptor
However, by the 1990s novel receptors were discovered mainly
by the identiﬁcation of their gene sequence and less so by
their pharmacology. The cloning of the receptor cDNA for
the human H1R and H2R were described in the early 1990s
(Gantz et al., 1991; De Backer et al., 1993), but the sequence
of the H3R remained elusive despite much work looking for
sequences with similarity to the H1R and H2R. The break-
through came using a diﬀerent approach where sequences were
identiﬁed that contained general homologies to GPCR (e.g.,
predicted seven transmembrane domains and other common
residues). These putative orphan GPCR genes were then screened
for binding to likely ligands. Using such an approach, a novel
sequence was discovered that encoded a GPCR that bound to his-
tamine and had pharmacology that matched that described for
the H3R (Lovenberg et al., 1999). The details of the sequence
revealed why the gene for the H3R was not found by a homol-
ogy approach, since it only exhibited ∼20% homology to the
H1R and H2R.
While the cloning of the H3R used an orphan GPCR/reverse
pharmacology approach, it yielded a receptor that was already
known and characterized on a pharmacological basis. The
discovery of the H4R truly started with the identiﬁcation
of an orphan GPCR. The discovery of the gene for the
H3R provided a tool for additional homology searches of
databases for related sequences. This yielded a putative recep-
tor that was ∼35% identical to the H3R and when expressed
in heterologous systems was found to have a high aﬃnity
for histamine (Liu et al., 2001). These genomic approaches
were so prevalent at the time that the identiﬁcation of
this new receptor, now known as the histamine H4 recep-
tor (H4R), was described almost simultaneously by six dif-
ferent laboratories (Nakamura et al., 2000; Oda et al., 2000;
Liu et al., 2001; Morse et al., 2001; Nguyen et al., 2001;
Zhu et al., 2001). Unlike the H3R, the H4R was com-
pletely novel and its function was unknown. However, one
hint of function was evident from the expression pattern
described in the original cloning papers that showed a
fairly selective expression on bone marrow and hematopoi-
etic cells known to be involved in inﬂammatory and immune
responses.
Development of Selective Ligands
The identiﬁcation of a novel histamine receptor, its expression
mainly on cells involved in immune responses coupled with the
successful history of drugs that target the H1R and H2R gener-
ated immediate interest (Hough, 2001). However, deorphanizing
the receptor was only the beginning. Importantly, selective lig-
ands were needed to be able to understand the function of the
receptor. The receptor has a relatively high homology to the H3R
and thus it is not surprising that many of the compounds previ-
ously described as H3R ligands also had aﬃnity for the H4R (Liu
et al., 2001). These ligands included (R)-α-methylhistamine, an
H3R agonist, and thioperamide, an H3R antagonists, but because
these ligands had aﬃnity for both receptors they are not ideal
tools for understanding the function of the H4R. The ﬁrst potent
and selective H4R antagonist was JNJ 7777120 (Jablonowski et al.,
2003). This compound has a high aﬃnity for the H4R and is
highly selective relative to other histamine receptors (Thurmond
et al., 2004).
JNJ 7777120 has become an excellent tool for understanding
the physiological role of the H4R and has been used exten-
sively in vitro cell models and in animal models. The use of JNJ
7777120 in vivo provided the ﬁrst evidence that H4R antagonists
could have anti-inﬂammatory properties. Neutrophil inﬂux in a
mouse peritonitis model was reduced upon pretreatment with
JNJ 7777120 (Thurmond et al., 2004). Early work also showed
that JNJ 7777120 and its analog, JNJ 10191584, were also eﬃca-
cious in a rat colitis model (Varga et al., 2005). This compound
along with other H4R antagonists have shown activity in models
of asthma, dermatitis, pain, and pruritus among others (Table 1;
Dunford et al., 2006, 2007; Cowden et al., 2010b; Hsieh et al.,
2010).
As evidenced by the pharmacology of the other histamine
receptors, it is important not to rely on the data provided by
a single ligand when assigning function to a particular recep-
tor. The reason for this is that despite the best eﬀorts it is
almost impossible to completely understand the pharmacol-
ogy of any ligand and how it may diﬀer in diﬀerent species,
cell types, or conditions. Because of these factors, researchers
must use a combination of tools including agonist/antagonist
pairs, ligands from diﬀerent chemical classes, and/or knock-
out animals before making conclusions about the function of
receptor. The use of a single ligand only gives ﬁrm conclusions
about the action of that ligand under the given experimental
conditions.
This has been highlighted as a potential issue with JNJ 7777120
as it has been described as having agonistic eﬀects at the H4R of
some species in some, but not all, transfected cell models and has
been described to drive functional selectivity, i.e., arrestin activa-
tion, of the H4R (Seifert et al., 2011). However, while these other
pharmacological eﬀects may exist, most of the current data sup-
port the fact that JNJ 7777120 is an antagonist in vivo and in
primary cells. For example the eﬀects on JNJ 7777120 in models
of asthma, dermatitis, arthritis, pain, and peritonitis are consis-
tent to those of other distinct H4R ligands and in H4R-deﬁcient
mice (Table 2; Thurmond et al., 2004, 2014a; Dunford et al.,
2006; Coruzzi et al., 2007; Altenbach et al., 2008; Cowart et al.,
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TABLE 1 | Effects of H4R antagonists in selected animal models1.
Disease models Effect Reference
Asthma Decreased BAL eosinophils and lymphocytes
Decreased IL-5, IL-4, IFNγ , IL-17, PGD2, LTB4, and TNF levels
Decreased lung T cells, CCL3, CCL5, mucin, and collagen
Increased lipocortin-1
Decreased antigen specific IgE and IgG1 levels
Decreased airway inflammation
Decreased cough and dyspnea
Decreased lung resistance, tissue stiffness, and tissue dampening
Dunford et al. (2006), Cowden et al. (2010a), Beermann et al.
(2012), Somma et al. (2013), Thurmond et al. (2014a)
Dermatitis In acute FITC dermatitis model reduced inflammation, skin eosinophils and mast
cells, IL-4, IL-6, TNF, MIP1α, IL-1β, MCP-1, GM-CSF, RANTES, and KC levels
No effect in other acute hapten models or in dog
In chronic models reduced skin lesions, skin eosinophils and mast cells, IgE, IL-4,
IL-5, IL-6, TSLP, TARC, and NGF levels
Rossbach et al. (2009), Cowden et al. (2010b), Seike et al.
(2010), Baeumer et al. (2011), Suwa et al. (2011), Matsushita
et al. (2012), Ohsawa and Hirasawa (2012), Thurmond et al.
(2014a)
Pruritus Reduced histamine-induced scratching
Reduced scratching in acute hapten models
Reduced scratching in chronic hapten models
Dunford et al. (2007), Cowart et al. (2008), Cowden et al.
(2010b), Liu et al. (2008), Rossbach et al. (2009), Yamaura et al.
(2009), Koenig et al. (2010), Suwa et al. (2011), Ohsawa and
Hirasawa (2012), Shin et al. (2012), Savall et al. (2014)
EAE Increased clinical score, demyelination, and inflammation
Increased IFNγ and IL-17
Reduced IL-4 and IL-10
Ballerini et al. (2013)
Arthritis Decreased severity score
Decreased inflammation, pannus formation, cartilage and bone damage
Decreased Th17 cells and IL-17 production
Cowden et al. (2014)
Pain Reduced inflammatory, neuropathic, and post-operative pain Cowart et al. (2008), Liu et al. (2008), Hsieh et al. (2010)
Colitis Reduced lesion area
Reduced tissue TNF and neutrophil levels
Varga et al. (2005)
1BAL, bronchoalveolar lavage; EAE, experimental autoimmune encephalomyelitis.
TABLE 2 | Effects of H4R-deficient mice in selected animal models1.
Disease models Effect Reference
Asthma Decreased BAL eosinophils, macrophages, and lymphocytes
Decreased IL-5, IL-4, IL-6, IL-17 levels
Decreased antigen specific IgE and IgG1 levels
Dunford et al. (2006)
Dermatitis Reduced inflammation in FITC-induced dermatitis Cowden et al. (2010b)
Pruritus Reduced histamine-induced scratching
Reduced hapten-induced scratching
Dunford et al. (2007), Cowden et al. (2010b)
EAE Increased clinical score, demyelination, and inflammation
Decreased Treg, increased Th17 cells
del Rio et al. (2012)
Arthritis Decreased severity score
Decreased inflammation, pannus formation, cartilage and bone damage
Cowden et al. (2014)
1BAL, bronchoalveolar lavage; EAE, experimental autoimmune encephalomyelitis.
2008; Liu et al., 2008; Cowden et al., 2010b, 2014; Hsieh et al.,
2010; Shin et al., 2012; Savall et al., 2014). Perhaps one of the
best examples of this is in the role of the receptor in mediating
pruritic responses in mice. Dunford et al. (2007) reported that
histamine-induced scratching in mice could be blocked by JNJ
77777120 and did not occur in H4R-deﬁcient mice. Furthermore,
other H4R agonists also induce scratching that can be blocked
by JNJ 7777120, but cannot induce scratching in H4R-deﬁcient
mice (Dunford et al., 2007; Yu et al., 2010). Other H4R antag-
onists with diﬀerent chemical structure also block this response
(Cowart et al., 2008; Liu et al., 2008; Koenig et al., 2010; Shin
et al., 2012; Savall et al., 2014). The data then clearly support
the role of JNJ 77777120 as an antagonist for this eﬀect. The
compound reverses the eﬀect of agonists, mimics the ﬁndings in
animal lacking the H4R and the results are replicated by other
antagonists. However, this cannot be generalized. For example
JNJ 7777120 also has been shown to block substance P induced
itch (Yamaura et al., 2009) and while is it appropriate to specu-
late that H4R activation is involved in substance P induced itch
based on data in other models, it would take studies in H4R-
deﬁcient mice or with other structurally distinct antagonist to
ﬁrmly conclude this.
Some of the in vivo data also yield insight as to the role
of functional selectivity at the H4R. In the models of pruritus,
asthma, and dermatitis the phenotype is the same between JNJ
7777120-treated and H4R-deﬁcient mice (Dunford et al., 2006,
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2007; Cowden et al., 2010b). This suggests that if the induction
of β-arrestin shown by Rosethorne and Charlton (2011) occurs
in mice (currently functional selectivity has only been studied for
the human receptor), it has little impact on the activity of the
compound in these models. For if JNJ 7777120-induced arrestin
pathways are anti-inﬂammatory then they would not exist in
the receptor deﬁcient animals. Once again the most likely expla-
nation is that the compound functions as an antagonist of the
receptor. This does not mean, however, that the possibility of
functional selectivity should be dismissed and it may suggest
that antagonists could be created that only block a subset of the
pathways activated by the receptor.
Function
Much of the original expression data obtained with the H4R
pointed to expression on cells involved in immune responses. In
conjunction with this, researchers took advantage that the lig-
and for this orphan receptor was histamine and thus searched
the extensive literature on histamine to ﬁnd functions medi-
ated by histamine, but where the pharmacology did not clearly
point to the H1R, H2R, or H3R. One example of this was
in eosinophils. In Clark et al. (1975) showed that histamine
could induce chemotaxis of human eosinophils at low concen-
trations, 10−7 and 10−6 M, but that at 10−5 M chemotaxis was
reduced. They showed that neither mepyramine (an H1R antag-
onist) nor metiamide (an H2R antagonist) had any eﬀect on the
enhanced chemotaxis, but that metiamide reversed the inhibition
of chemotaxis at 10−5 M. They concluded that the stimulation
of chemotaxis by histamine was independent of H1R and H2R
and in a later paper concluded that a third histamine receptor
existed on eosinophils (this was prior to the discovery of the H3R;
Clark et al., 1977). Raible et al. (1992) showed that histamine
induced a calcium response in eosinophils and, as observed for
chemotaxis, this eﬀect was not inhibited by an H1R antagonist
(mepyramine) or an H2R antagonist (cimetidine). The calcium
response was inhibited by thioperamide which was described as
an antagonist of the newly discovered H3R. In addition (R)-α-
methylhistamine, an H3R agonist, induced a calcium response
similar to that of histamine. However, the authors commented
that the fact that (R)-α-methylhistamine was less potent than
histamine suggested that this calcium response was not medi-
ated by a classic H3R since at this receptor histamine is more
potent than (R)-α-methylhistamine. In a later study Raible et al.
(1994) conﬁrm this unusual pharmacology with a series a dif-
ferent H3R antagonists and agonists. The identity of this novel
histamine receptor remained a mystery (or was perhaps ignored)
until the discovery of the gene for the H4R. It was noted that the
pharmacological proﬁle of the H4R was similar to the receptor
described by Raible et al. (1994; Oda et al., 2000; Hough, 2001;
Liu et al., 2001; Morse et al., 2001; Zhu et al., 2001; O’Reilly et al.,
2002). In particular, burimamide is a weak H4R partial agonist
(Zhu et al., 2001; Lim et al., 2005), while (R)-α-methylhistamine
and N-methylhistamine are both full agonist (Nakamura et al.,
2000; Oda et al., 2000; Liu et al., 2001; Morse et al., 2001; Zhu
et al., 2001), but are less potent than histamine thus matching
the conﬂicting pharmacology described by Raible et al. (1992,
1994). The role of the H4R in mediating histamine-induced
eosinophil chemotaxis and calcium responses was conﬁrmed
once selective ligands became available. Selective H4R antagonists
(e.g., JNJ 7777120) have been shown to block histamine-induced
chemotaxis and calcium responses (Ling et al., 2004; Strakhova
et al., 2009; Reher et al., 2012; Shin et al., 2012). Chemotaxis of
eosinophils can also be studied indirectly by measuring shape-
change related to actin reorganization that precedes chemotaxis
(Sabroe et al., 1999). Histamine and selective H4R agonists such
as 4-methylhistamine and others have been shown to induce
eosinophil shape change and this can be blocked by H4R selec-
tive antagonists (Ling et al., 2004; Lim et al., 2005; Yu et al., 2010;
Shin et al., 2012; Thurmond et al., 2014a).
The histamine-induced eosinophil shape change was used
as a pharmacodynamics readout for a clinical study with JNJ
39758979 (Thurmond et al., 2014a). After oral dosing of the com-
pound to healthy volunteers, blood samples were taken at various
timepoints, stimulated with histamine and the shape change of
the eosinophils was assessed. At doses and time points where
the concentration of JNJ 39758979 was above 100 nM, a statis-
tically signiﬁcant inhibition was observed. This level of potency
was similar to what when the compound was added to blood in
vitro (Thurmond et al., 2014a). These results show that in vivo
administration of an H4R antagonist in humans can have impact
on eosinophil function.
The initial idea that a new histamine receptor was present
on eosinophils came about because of diﬀerences in the phar-
macology of various histamine ligands. Not only were H1R and
H2R ligands ineﬀective, but the potency of H3R ligands was
not as expected (Raible et al., 1994). Therefore, it is impor-
tant to evaluate the pharmacological data with the H4R lig-
ands carefully. First, it has been noted that the potency for
eosinophil function of the various H4R ligands (either selective
or non-selective) compared to histamine is in general agree-
ment with their relative aﬃnities thus supporting that this is
in fact the H4R (Buckland et al., 2003; Ling et al., 2004; Lim
et al., 2005; Yu et al., 2010; Reher et al., 2012). Furthermore,
the Ki for antagonists can be calculated from studies where the
EC50 of histamine is given using modiﬁcations of the Cheng
and Prusoﬀ (1973) equation. Ling et al. (2004) report IC50 val-
ues for JNJ 7777120 and thioperamide for eosinophil shape
change and chemotaxis. One can use these values along with
the concentration and EC50 for histamine to calculate Ki val-
ues of 5 and 4 nM for JNJ 7777120 and 26 and 26 nM for
thioperamide for inhibiting histamine-induced eosinophil shape
change and chemotaxis, respectively. These numbers are simi-
lar to the reported Ki values from recombinant systems for JNJ
7777120 (4 nM) and thioperamide (27 nM; Liu et al., 2001;
Thurmond et al., 2004). Consistent with this Barnard et al. (2008)
report an IC50 of JNJ 7777120 of 6 nM that corresponds to
a calculated Ki value of 2 nM. However, Seifert et al. (2011)
have stated incorrectly that the discrepancy in the IC50 values
for JNJ 7777120 between the Ling et al. (2004) and Barnard
et al. (2008) studies (300 versus 6 nM) support the notion of
functional selectivity for the H4R in eosinophils. However, the
authors fail to take into account the diﬀerences in EC50 for
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histamine 19 nM for Ling et al. (2004) and 150 nM for Barnard
et al. (2008), which when properly accounted for yields almost
identical Ki values for JNJ 7777120 (5 nM versus 2 nM). The
diﬀerences in the EC50 for histamine between the two studies is
most likely due to large diﬀerences in histamine response related
to H4R levels between diﬀerence donors as reported by Yu et al.
(2010).
The eﬀect of JNJ 7777120 on the histamine calcium response
in eosinophils yields the same conclusion with a reported Ki value
of 1.3 nM (Reher et al., 2012). However, these same authors report
a discrepancy in the Ki values for JNJ 7777120 with respect to
chemotaxis. The calculated Ki for JNJ 7777120 was 9.8 nM when
histamine was used to induce chemotaxis, but 1.6 nM when a
selective H4R agonist was used, UR-PI376 (Reher et al., 2012).
They use this data as “evidence for ligand-speciﬁc receptor con-
formation” as the title states. However, the authors fail to account
for the role of the H2R in inhibiting chemotaxis. The Ki value of
9.8 nM is calculated using the EC50 of histamine (120 nM), but
this is not a true EC50 since the dose response curve is made up of
two components – one for the H4R response and one for the H2R
response. Indeed when the authors block the H2R with famoti-
dine, the EC50 of histamine is reduced to 39 nM. Recalculating
the Ki for JNJ 7777120 using this EC50, which represents the
true H4R response, yields a value of 3.2 nM that is completely
consistent with the value when using the H4R-selective ago-
nist and the value reported by Ling et al. (2004). Furthermore,
this value is similar to the Ki value the authors report for the
histamine-induced calcium response because there is no H2R
contribution to the calcium signal as shown in the paper (Reher
et al., 2012). Therefore, the eﬀects seen by H4R ligands on
eosinophil responses are entirely consistent with the known phar-
macology of the H4R and no functional selectivity needs to be
invoked.
Histamine is largely associated with mast cells since these
cells store and secrete large amounts of histamine. Therefore,
it was natural early to look for H4R eﬀects in mast cells. One
of the major functions of mast cells it to release inﬂammatory
mediators such as histamine upon IgE-mediated degranulation.
However, in mouse bone marrow-derived mast cells, neither
genetic deﬁciency (mast cells taken fromH4R-deﬁcient mice) nor
the H3R/H4R antagonist thioperamide had any eﬀect on antigen-
mediated degranulation (Hofstra et al., 2003). The H4R does
appear to modulate degranulation indirectly by inducing upreg-
ulation of high aﬃnity IgE receptors, FcεRI (Mirzahosseini et al.,
2013). In addition to this, in human mast cells histamine and
4-methylhistamine on their own were able in induced degranu-
lation and in both cases this could be blocked with JNJ 7777120
(Jemima et al., 2014). As for eosinophils, histamine acting via
the H4R can induce increases in intracellular calcium. This
histamine-induced calcium response is not present in mast cells
from H4R-deﬁcient mice and can be blocked by thioperamide or
JNJ 7777120 (Hofstra et al., 2003; Thurmond et al., 2004; Jemima
et al., 2014). H4R agonists can also induce calcium responses in
these cells (Yu et al., 2010; Jemima et al., 2014). Also similar to
eosinophils, histamine-induced chemotaxis can be observed in
mast cells. This eﬀect was not observed with mast cells deﬁcient
in the H4R and can be blocked by antagonist of the H4R, but not
the other histamine receptors (Hofstra et al., 2003; Thurmond
et al., 2004, 2014a). As for the eosinophil data the IC50 values
for H4R antagonist was consistent with measured values indicat-
ing that the eﬀects seen are due to H4R antagonism (Thurmond
et al., 2004, 2014a). Changes in cell shape related to chemo-
taxis can also be measured and blocked by H4R antagonists
(Strakhova et al., 2009). Consistent with this, the H4R agonist 4-
methylhistamine can induce chemotaxis and this eﬀect is blocked
by JNJ 7777120 (Lim et al., 2005). In addition, histamine has
also been shown to potentiate the migration of human precursor
mast cells to the chemoattractant CXCL12 (Godot et al., 2007).
The histamine-induced migration of mast cells may be related to
the accumulation of mast cells at sites of inﬂammation. It has
been shown that inhalation of histamine by mice leads to an
accumulation of subepithelial mast cells in the trachea and this
was reversed upon pretreatment with JNJ 7777120 (Thurmond
et al., 2004). The number of mast cells increases in the skin
in mouse dermatitis models and in vivo treatment with JNJ
7777120 blocked this accumulation (Cowden et al., 2010b; Seike
et al., 2010; Suwa et al., 2011; Matsushita et al., 2012; Ohsawa
and Hirasawa, 2012). In addition to inducing chemotaxis, the
H4R also enhances inﬂammatorymediator production frommast
cells. In mouse mast cells, histamine and 4-methylhistamine were
both able to induce IL-6 production on their own and potenti-
ate the IL-6 production driven by LPS stimulation. These eﬀects
were mediated via the H4R since they could be blocked by
H4R antagonists and were not present in H4R-deﬁcient mice
(Desai and Thurmond, 2011). In human mast cells the H4R
mediated the release of leukotrienes, cytokines, and chemokines
(Jemima et al., 2014).
The eﬀects on mast cells and eosinophils pointed to allergic
diseases such atopic dermatitis and asthma. The FITC-induced
dermatitis model inmice is a contact dermatitis model, but unlike
other models is characterized by eosinophilia. Mice deﬁcient in
the H4R, have reduced inﬂammation in this model as judged by
a reduction in inﬂammatory cytokines and chemokines in the
skin and a reduction in swelling at the site of FITC challenge
(the ear; Cowden et al., 2010b). Several diﬀerent H4R antago-
nists also show the same eﬀect (Cowden et al., 2010b; Thurmond
et al., 2014a). At the site of FITC application there is a increase
in both the number of eosinophils and mast cells in the skin.
Treatment of the mice systemically with JNJ 7777120 was able
to reduce, and for mast cells completely block, this increase
(Cowden et al., 2010b). The H4R does no play a role in all acute
dermatitis models. For example, no eﬀect was observed with H4R
antagonists in an acute canine atopic dermatitis model or when
2,4-dinitrochlorobenzene or toluene-2,4-diisocyanate were used
as the hapten in mice (Rossbach et al., 2009; Baeumer et al., 2011).
The same lack of eﬀect was reported with JNJ 7777120 in an acute
model using the hapten 2,4,6-trinitro-1-chlorobenzene (TNCB;
Seike et al., 2010). However, when TNCB was given chronically
the administration of JNJ 7777120 reduced the inﬂammation,
the levels of inﬂammatory cytokines, and the number of mast
cells and eosinophils in the skin (Seike et al., 2010; Suwa et al.,
2011; Matsushita et al., 2012). A reduction in inﬂammation by
JNJ 7777120 was also observed in the NC/Nga mouse model of
chronic allergic dermatitis (Ohsawa and Hirasawa, 2012). One
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explanation for the disconnect between some of the acute and
chronic hapten models may be accounted for by diﬀerences in
the cell types involved in the inﬂammation, i.e., Th1 versus Th2
cells.
Another disease typically associated with eosinophils andmast
cells is asthma. The lack of eﬀect for treating asthma with antag-
onists that target the H1R and H2R has led many to question
the role of histamine in the disease (Thurmond et al., 2008).
However, it is possible that histamine acts via the H4R to drive
some of the pathophysiology of asthma. In support for a role
of the H4R in asthma, polymorphisms in the gene have been
associated with infection-induce asthma (Simon et al., 2012). In
addition H4R-deﬁcient mice are protected in a mouse asthma
model (Dunford et al., 2006). These mice have fewer eosinophils
in bronchoalveolar lavage ﬂuid, reduced inﬂammatory cytokines,
and decreased antigen speciﬁc IgE and IgG1 levels after aller-
gen challenge (Dunford et al., 2006). Treatment with the H4R
antagonists JNJ 7777120, JNJ 10191584, or JNJ 39758979 during
allergen challenge also reduced the eosinophilia (Dunford et al.,
2006; Cowden et al., 2010a; Beermann et al., 2012; Neumann
et al., 2013; Thurmond et al., 2014a). Improvement in lung func-
tion has also been shown upon treatment with an H4R antagonist
and in H4R-deﬁcient mice (Cowden et al., 2010a; Hartwig et al.,
2014). Similar eﬀects have been reported in a guinea pig model,
where JNJ 7777120 improved lung function, reduced inﬂamma-
tion, eosinophilia, and inﬂammatory mediator production in the
lung after allergen challenge (Somma et al., 2013). All of these
data point to a therapeutic potential for H4R antagonist for the
treatment of asthma.
One unexpected ﬁnding in the mouse asthma models was
that mast cells were not needed for the H4R response. Dunford
et al. (2006) showed that the inhibition of lung eosinophilia and
inﬂammatory cytokines levels by an H4R antagonist was still
present in mice lacking mast cells. The model used in this case
is known to be dependent on T cells and not mast cells (Komai
et al., 2003), suggesting that T cells may be the main contribu-
tor to the H4R response. To support the eﬀect of the H4R on T
cells, JNJ 7777120 was dosed only around the sensitization in the
asthma model when antigen speciﬁc T cells are being generated.
As with the dosing at allergen challenge, treatment with the H4R
antagonist at sensitization reduced the number of eosinophils and
the inﬂammatory cytokines (Dunford et al., 2006). These results
coupled with the fact that the H4R antagonists worked in mod-
els known to be T cell dependent suggested that the receptor was
playing a role in the priming and activation of T cells. This eﬀect
is reﬂected in the reduction in Th2 cytokines such as IL-4, IL-5,
and IL-13 in BAL ﬂuid or upon restimulation of splenocytes or
lymphocytes (Dunford et al., 2006; Cowden et al., 2010a; Somma
et al., 2013; Hartwig et al., 2014). The activation of T cells may
also be the primary target in the models of atopic dermatitis as
reduction in Th2 cytokines have been reported in the skin after
treatment with an H4R antagonist (Cowden et al., 2010b; Seike
et al., 2010; Matsushita et al., 2012; Ohsawa and Hirasawa, 2012).
There are several possible mechanisms for the H4R eﬀect
on T cells. In both asthma and dermatitis models treatment
with an H4R antagonist reduced the number of T cells at the
site of inﬂammation (Cowden et al., 2010a; Mahapatra et al.,
2014). The reduction may be a result of decreases in the pro-
duction of chemokines (Cowden et al., 2010a,b) or direct eﬀects
of histamine as a chemoattractant for T cells (Bryce et al., 2006;
Morgan et al., 2007). Expression of the H4R has been reported
on human Th2 cells and H4R agonists increased the expres-
sion of IL-31 (Gutzmer et al., 2009). The eﬀects on T cells may
also be indirect as there is evidence that the H4R is involved in
dendritic cell function and may drive the response in asthma.
When H4R-deﬁcient dendritic cells where used to polarize T
cells in vitro, these T cells there not able to transfer disease
in a mouse adoptive transfer asthma model (Hartwig et al.,
2014). This was not the case when H4R-deﬁcient T cells were
used. In addition, wild-type T cells could not transfer disease
in H4R-deﬁcient mice suggesting that it is the H4R on other
cells such as dendritic cells that are important for driving dis-
ease (Hartwig et al., 2014). One possible role for the H4R in
dendritic cells is in mediating migration of the cells to the site
of interaction with T cells, since it has been shown that the
migration of antigen positive dendritic cells from the skin to the
lymph node was reduced upon treatment with an H4R antag-
onist (Cowden et al., 2010b). As for T cells, these eﬀects may
be a result of H4R directly mediating migration via histamine
acting a chemoattractant (Gutzmer et al., 2005; Damaj et al.,
2007; Bäumer et al., 2008; Gschwandtner et al., 2010, 2011)
or indirectly by reduction in chemokine production (Cowden
et al., 2010a,b). The H4R may also impact activation of den-
dritic cells. Dendritic cells from H4R-deﬁcient mice or treated
in vitro with an H4R antagonists were defective in their abil-
ity to activate Th2 cells (Dunford et al., 2006). Similarly, when
human monocyte derived dendritic cells were treated with JNJ
7777120 the levels of MHC and costimulatory molecules were
reduced and these cells were unable to induce allergen-speciﬁc
proliferation of T cells (Lundberg et al., 2011). In addition to
eﬀects on dendritic cell maturation, the H4R modulates cytokine
and chemokine production by dendritic cells that may result
in defective T cell activation (Gutzmer et al., 2005; Dunford
et al., 2006; Dijkstra et al., 2008; Gschwandtner et al., 2010,
2011, 2012). Dendritic cells can be activated by endogenous
danger signals action via toll-like receptors (TLRs). Activation
of dendritic cells in vitro with TLR ligands leads to the pro-
duction of cytokines and chemokines and this can be modu-
lated by H4R antagonists (Gutzmer et al., 2005; Dunford et al.,
2006; Dijkstra et al., 2008; Gschwandtner et al., 2010, 2011,
2012). In vivo H4R antagonist can inhibit LPS (a TLR lig-
and) induced production of inﬂammatory cytokines and this
is also reduced in H4R-deﬁcient mice (Cowden et al., 2013).
This link between TLR and H4R may important driving asth-
matic responses since it has been shown that H4R antagonists
are only eﬀective in mouse asthma models when LPS is present
(Cowden et al., 2013).
The role for the H4R in T cells pointed to possible roles in
other disease that are thought to be T cell mediated. In partic-
ular the autoimmune disease rheumatoid arthritis is thought to
be driven in part by T cell responses as evidenced by the clin-
ical eﬃcacy of abatacept, that targets the activation of T cells,
and the fact that there is a strong genetic association with the
human leukocyte antigen (HLA)-DRB1 and the presentation of
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antigens (Raychaudhuri et al., 2012; Gizinski and Fox, 2014).
Based on this, the role of the H4R in preclinical models of
rheumatoid arthritis has been explored. H4R-deﬁcient mice and
mice treated with the H4R antagonist JNJ 28307474 were pro-
tected from disease in both a mouse collagen-induced arthritis
and collagen antibody-induced arthritis model (Cowden et al.,
2014). This was reﬂected in an improvement in disease severity
score and in the histologic analysis of the joints. The anti-
inﬂammatory eﬀects can be observed either with dosing at the
onset of disease or at the peak of disease activity. A second
selective H4R antagonist, JNJ 39758979, has also shown activ-
ity in the collagen-induced arthritis model (Savall et al., 2014).
However, the eﬀect on T cells may not translate into eﬃ-
cacy in all autoimmune diseases. H4R-deﬁcient mice or mice
treated with an H4R antagonist had signiﬁcantly worse disease
in mouse experimental autoimmune encephalomyelitis mod-
els of multiple sclerosis (del Rio et al., 2012; Ballerini et al.,
2013).
The collagen-induced arthritis model is known to be driven
by the production of IL-17 from Th17 cells (Lubberts et al.,
2001; Nakae et al., 2003; Lubberts et al., 2004). Treatment with
the H4R antagonist in this model decreased the production of
IL-17 from lymphocytes and reduced the number of IL-17 pos-
itive CD4 cells (Th17 cells) in the inguinal lymph node, but
had no eﬀect on the production of IFNγ. H4R antagonists also
blocked the diﬀerentiation of Th17 cells in vitro and reduc-
tion in IL-17 production has also been reported in models of
asthma and dermatitis (Dunford et al., 2006; Cowden et al.,
2010b, 2014). As for the asthma model, the eﬀects on T cells
could be direct or indirect. For the collagen antibody-induced
model, adoptive transfer of wild-type dendritic cells (splenic
CD11c+ cells) restored disease in H4R-deﬁcient animals sug-
gesting that the H4R on antigen presenting cells was crucial
for disease activity (Cowden et al., 2014). This is also sug-
gested when Th17 development was studied directly in vivo using
an adoptive transfer model. The H4R antagonist blocked the
Th17 diﬀerentiation of transgenic T cells in vivo. In addition
the transfer of wild-type transgenic T cells into H4R-deﬁcient
host mice also resulted in a reduction in Th17 cells support-
ing the conclusion that the H4R on host antigen presenting
cells is important (Cowden et al., 2014). However, this may
not be the complete story as transfer of H4R-deﬁcient trans-
genic T cells into wild-type host also lead to a reduction in
Th17 cells indicating that the H4R on T cells is also important.
Expression the H4R has been reported on human and mouse
Th17 cells (Mommert et al., 2012; Cowden et al., 2014). In iso-
lated human Th17 cells H4R agonist increased the production
of IL-17 and this was reduced by an H4R antagonist suggest-
ing that the receptor can have a direct eﬀect on Th17 cells
(Mommert et al., 2012).
Pruritus is another process that has long been associated
with histamine (for a review see Thurmond et al., 2014b). In
fact, injection of histamine into the skin of humans causes
the sensation of itching. Antihistamines that target the H1R
have exhibited eﬃcacy in reducing itch in a number of con-
ditions such as acute urticaria and allergic rhinitis. However,
the itch associated with other pruritic diseases such as atopic
dermatitis is not well-controlled by these drugs. The discov-
ery of the H4R prompted the exploration as to whether this
receptor could be responsible for pruritic responses not driven
by the H1R. Injection of histamine into the skin of mice
causes a scratching response. This response can be inhib-
ited by the administration of H4R antagonists (Bell et al.,
2004; Dunford et al., 2007; Yamaura et al., 2009; Shin et al.,
2012; Savall et al., 2014). Histamine-induced scratching is
also reduced in H4R-deﬁcient mice (Dunford et al., 2007).
Injection of H4R agonists can induce scratching and this
is inhibited with H4R antagonists or in H4R-deﬁcient mice
(Dunford et al., 2007; Cowart et al., 2008; Liu et al., 2008;
Koenig et al., 2010; Yu et al., 2010). H4R antagonists can
also inhibit scratching in mice induced by substance P, hap-
tens, and in models of dermatitis (Rossbach et al., 2009;
Yamaura et al., 2009; Cowden et al., 2010b; Suwa et al.,
2011; Ohsawa and Hirasawa, 2012). These data have prompted
the study of the anti-pruritic eﬀects of H4R antagonists in
humans.
Clinical Data
There have only been a few reports of clinical data with H4R
antagonists. The compound with the most published informa-
tion is JNJ 39758979. JNJ 39758979 is a potent and selective H4R
antagonist that has eﬃcacy in preclinical models of pruritus, der-
matitis, asthma, and arthritis (Savall et al., 2014; Thurmond et al.,
2014a). This H4R antagonist has been used to explore the role of
the receptor in mediating histamine-induced pruritus in humans
(NCT01068223). Over three periods subjects received either a
single dose of JNJ 39758979, the H1R antagonist cetirizine, or
placebo. At 2 and 6 h after dosing, histamine was injected intra-
dermally into the skin of the forearm of each subject and the
pruritic response was assessed by having the subject rate the itch
sensation on 1–10 scale over a 10 min period (Kollmeier et al.,
2014). JNJ 39758979 reduced the itch sensation induced by his-
tamine at both 2 and 6 h after dosing, whereas placebo had no
eﬀects. Cetirizine was used as a positive control and it reduced
the pruritic response at 6 h post-dose as expected. This data val-
idates the preclinical ﬁndings in mice and shows that the H4R
is involved in mediating pruritic responses in humans. This sug-
gests that H4R antagonists will have utility in humans in treating
pruritic conditions known to be mediated by histamine such as
acute urticaria and allergic rhinitis. Of potential interest is the
drug alcaftadine that is a topical ophthalmic solution indicated
for the prevention of itching associated with allergic conjunctivi-
tis. This compound has weak activity at the H4R as well as being a
potent H1R antagonist and this diﬀerentiates it from other topical
treatments such as olopatadine that has no H4R activity (Gallois-
Bernos and Thurmond, 2012). Preclinical data indicate that the
combination of H4R and H1R may yield better eﬃcacy against
pruritus than an H1R alone (Dunford et al., 2007; Nakano et al.,
2009; Rossbach et al., 2009; Cowden et al., 2010b; Ohsawa and
Hirasawa, 2012). This may also be true in humans as an analy-
sis across two clinical eﬃcacy studies indicated that alcaftadine
exhibited greater eﬃcacy in reducing ocular itch compared to
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olopatadine after conjunctival allergen challenge (McLaurin et al.,
2014).
One pruritic condition where the itch is not well controlled by
H1R antagonists is atopic dermatitis, which is a common inﬂam-
matory pruritic skin disease. Pruritus is one of the most com-
mon and characteristic symptoms of atopic dermatitis (Williams,
2005). Several clinical trials have been conducted to evaluate the
eﬃcacy of H1R antagonists for the reduction of pruritus asso-
ciated with atopic dermatitis, with limited evidence for eﬃcacy
(Klein and Clark, 1999; Akdis et al., 2006; Saeki et al., 2009). These
observations prompted the study of H4R antagonists in pre-
clinical dermatology models and indicated that such antagonists
could be eﬃcacious (Cowden et al., 2010b; Seike et al., 2010; Suwa
et al., 2011; Matsushita et al., 2012; Ohsawa and Hirasawa, 2012).
Evidence that H4R can be eﬃcacious against atopic dermatitis in
humans has been provided in the clinical with JNJ 39758979. A
phase 2a study in adults with moderate atopic dermatitis com-
pared two doses of JNJ 39758979 versus placebo (Murata et al.,
2015). Unfortunately, the study was terminated before all subjects
completed the treatment period due to two cases of agranulocy-
tosis that was most likely related to reactive metabolites of the
compound and not to H4R antagonism (Murata et al., 2015).
Post hoc analysis indicated evidence of eﬃcacy. The primary
eﬃcacy was assessed at week 6 using eczema area and sever-
ity index (EASI) scores. There was a numerical reduction in the
EASI score for both 100 and 300 mg JNJ 39758979 compared
to placebo, but these changes were not statically signiﬁcant. The
EASI score does not include any direct measurements of pruri-
tus, which is the most common and characteristic symptom of
atopic dermatitis, and therefore several secondary endpoints were
include to assess pruritus. Across all of these endpoints there was
a strong and nominally statistically signiﬁcant reduction in the
pruritus sensed by patients on JNJ 39758979 (Murata et al., 2015).
Therefore although there are caveats with the interpretation of
the results and issues with the safety of JNJ 39758979, it appears
that other safer H4R antagonists could have utility in the treat-
ment of atopic dermatitis especially with respect to reducing
pruritus.
In addition to the published studies a study with JNJ 39758979
in patients with persistent asthma (NCT00946569) has been com-
pleted, but no data has been reported. In addition to this other
H4R antagonists have been reported to be in the clinic such as
UR-63325, PF-3893787, and toreforant (JNJ 38518168), the ﬁrst
H4R antagonist with a generic name. ClinicalTrials.gov indicates
that UR-63325 has completed a nasal allergen challenge study in
patients with allergic rhinitis (NCT01260753) and PF-3893787
a bronchial allergen challenge study in patients with asthma
(NCT00856687), but no results have been reported. Toreforant
has completed eﬃcacy studies in patients with rheumatoid
arthritis (NCT01679951, NCT00941707, and NCT01862224).
Results for these studies have not been reported, but it was
noted that a dose range ﬁnding study in rheumatoid arthritis
(NCT01679951) was terminated for lack of eﬃcacy. Studies with
toreforant in patients with asthma (NCT01823016) and psoriasis
(NCT02295865) were ongoing as of February 2015.
Conclusion
The story of the H4R provides an excellent case study for the
deorphanization of a novel receptor and the translation of this
into clinical eﬃcacy in humans. The gene for the receptor was
discovered via genomic homology searches and reverse pharma-
cology led to the identiﬁcation of its role in immune and pruritic
responses. This work has now resulted in the ﬁrst reports of clin-
ical eﬃcacy for H4R antagonists and point to the potential of
these ligands as future drugs for the treatment of a variety of
indications.
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